Candel publishes phase 3 prostate cancer trial data in Lancet Oncology

June 2, 2026 8:05 AM

Candel Therapeutics Inc. (NASDAQ: CADL) announced the publication of results from its pivotal phase 3 clinical trial of aglatimagene besadenovec ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found